News | March 13, 2009

DAVID II Trial Results Shows No Clear Advantages in Pacing Mode

March 13, 2009 - Details from the DAVID (Dual Chamber and VVI Implantable Defibrillator) II Trial suggest atrial pacing may be considered a safe alternative to ventricular pacing, but affords no clear advantage over a mode that minimizes pacing.

The results of the study were published this week in the March 10, 2009, issue of the Journal of the American College of Cardiology (JACC).

The original DAVID Trial randomized patients with systolic dysfunction to dual chamber pacing at 70 beats/minute or back-up only pacing. More frequent pacing was associated with worsened outcomes.

Bruce L. Wilkoff, M.D., Cleveland Clinic, and colleagues hypothesized that the mode of pacing chosen for the trial (dual chamber rate-responsive pacing at 70 beats/min) was the culprit and that atrial pacing with native ventricular conduction would be superior to back-up only pacing. The DAVID II trial randomized 600 patients with systolic dysfunction who required an implanted defibrillator to atrial pacing at 70 beats/min versus minimal ventricular pacing at 40 beats/minute. They found there were no significant differences in the combined primary end point of time to death or heart failure hospitalization during follow-up, or in the rates of atrial fibrillation, syncope, and quality of life measures.

For more information:

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init